

Annex IV

**Conclusions on the request for one-year marketing protection presented by the European
Medicines Agency**

Conclusions presented by the European Medicines Agency on:

- **one-year marketing protection**

The CHMP reviewed the data submitted by the marketing authorisation holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.